Frank KriegSchneider - Mainz Biomed Chief Officer

MYNZ Stock  USD 7.32  0.40  5.78%   

Executive

Frank KriegSchneider is Chief Officer of Mainz Biomed BV
Age 62
Address Robert Koch Strasse 50, Mainz, Germany, 55129
Phone49 6131 554 2860
Webhttps://mainzbiomed.com

Mainz Biomed Management Efficiency

The company has return on total asset (ROA) of (0.9924) % which means that it has lost $0.9924 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (43.3371) %, meaning that it created substantial loss on money invested by shareholders. Mainz Biomed's management efficiency ratios could be used to measure how well Mainz Biomed manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.3 in 2024. Return On Capital Employed is likely to rise to -4.1 in 2024. At this time, Mainz Biomed's Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 7.7 M in 2024, whereas Total Assets are likely to drop slightly above 10.4 M in 2024.
Mainz Biomed BV currently holds 7.42 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Mainz Biomed BV has a current ratio of 10.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Mainz Biomed's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

LLM JDMDxHealth SA ADR
59
JD EsqApplied DNA Sciences
39
Claudia LeviDarioHealth Corp
N/A
Lisa MetznerRosasNeuronetics
N/A
Miriam ReyesMDxHealth SA ADR
51
Ron CPAMDxHealth SA ADR
50
Josh FischerDarioHealth Corp
N/A
Mary MooneyDarioHealth Corp
N/A
Omar MDDarioHealth Corp
N/A
Shane BowenStandard Biotools
N/A
Joseph SolleeMDxHealth SA ADR
59
Steven SpringmeyerBiodesix
N/A
Tomer BenKikiDarioHealth Corp
53
Brian HarriganDarioHealth Corp
N/A
Austin AertsSera Prognostics
37
Renaud MalobertiENDRA Life Sciences
55
Kieran OKaneBiodesix
47
Hoi LoPrenetics Global
39
Steve FreemanENDRA Life Sciences
N/A
Ziad RouagENDRA Life Sciences
N/A
Sanjay HurryApplied DNA Sciences
N/A
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States. Mainz Biomed BV (MYNZ) is traded on NASDAQ Exchange in USA. It is located in Robert Koch Strasse 50, Mainz, Germany, 55129 and employs 65 people. Mainz Biomed is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Mainz Biomed BV Leadership Team

Elected by the shareholders, the Mainz Biomed's board of directors comprises two types of representatives: Mainz Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mainz. The board's role is to monitor Mainz Biomed's management team and ensure that shareholders' interests are well served. Mainz Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mainz Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Corinna Gorges, Head RD
Chris PMP, Chief Officer
Frank KriegSchneider, Chief Officer
Darin Leigh, Chief Officer
Philipp Freese, Chief Officer
Petra Ploesser, Head Quality
Guido Baechler, CEO Director
William Caragol, Chief Officer
Stefan Erlach, Head Resources
Christopher PMP, Chief Officer
William CPA, Chief Officer
Moritz Eidens, Chief Director

Mainz Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mainz Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.